Ospedale Infermi di Rimini

Running trials

• Recruiting

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy

  NCT06994377· European Institute of Oncology· Source

• Recruiting

  Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation

  NCT03911193· Phase 2· Fondazione Ricerca Traslazionale· Source

• Recruiting

  MITO 31- A phase II trial of Olaparib in patients with recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes: The MITO 31 translational study.

  NCT04091204· Phase 2· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Source

• Recruiting

  Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

  NCT06472245· Phase 3· OSE Immunotherapeutics· Source

• Recruiting

  Master Framework For Relapse or Refractory Acute Myeloid Leukemia

  NCT06459024· Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS· Source

• Active, not recruiting

  TRanscatheter Aortic-Valve Implantation With or Without On-site Cardiac Surgery: the TRACS Trial

  NCT05751577· Azienda Usl di Bologna· Source

• Recruiting

  Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.

  NCT04662723· Phase 4· Fondazione Schena· Source

• Active, not recruiting

  Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

  NCT05563220· Phase 1/2· Stemline Therapeutics, Inc.· Source

• Recruiting

  Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

  NCT05009082· Phase 3· AGO Study Group· Source

• Recruiting

  Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera

  NCT06516406· IRCCS Azienda Ospedaliero-Universitaria di Bologna· Source

• Active, not recruiting

  Patient-Reported Outcomes in PHiladelphia-nEgative Cytogenetic mYeloproliferative Neoplasms (PROPHECY).

  NCT04378855· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source

• Recruiting

  Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)

  NCT04300101· Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS· Source

• Recruiting

  "Triple Negative" Adult B-cell Acute Lymphoblastic Leukemia - TRINEG-ALL

  NCT06919393· Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS· Source

• Active, not recruiting

  Functional Assessment in Elderly MI Patients With Multivessel Disease

  NCT03772743· Consorzio Futuro in Ricerca· Source

• Active, not recruiting

  Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma

  NCT03190525· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Ovarian cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukaemia1 recruiting
• Childhood cancers1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• IgA nephropathy1 recruiting
• Lung cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Myeloproliferative neoplasms1 recruiting

Closed trials

• Completed

  EmploYEd Antithrombotic Therapies in Patients With Acute Coronary Syndromes HOspitalized in iTalian CCUs

  NCT06316128· Heart Care Foundation· Source

• Completed

  Effect of Long-term Psoriasis on Patients' Life - CORONATE

  NCT05555953· AbbVie· Source

• Withdrawn

  To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer

  NCT05212701· Phase 2· Dompé Farmaceutici S.p.A· Source

• Recruiting

  A "Physician & Patient-powered" Cohort Registry (MY MYELOMA)

  NCT05001087· Fondazione EMN Italy Onlus· Source

• Terminated

  The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide

  NCT03804372· Phase 2· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source

• Completed

  A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma

  NCT03647124· Celgene· Source

• Completed

  Clinical and Laboratory Characteristics of Polycythemia Vera

  NCT06134102· IRCCS Azienda Ospedaliero-Universitaria di Bologna· Source

• Completed

  TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion"

  NCT03596385· Phase 4· Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III· Source

• Completed

  Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia

  NCT03367299· Phase 2· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source

• Completed

  Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia

  NCT02388048· Phase 2· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source

• Terminated

  Clinical Benefits of the Closed Loop Stimulation in Sinus Node Disease

  NCT02579889· Biotronik SE & Co. KG· Source

• Completed

  Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia

  NCT02232386· Phase 2· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source

• Completed

  A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

  NCT02158858· Phase 1/2· Constellation Pharmaceuticals· Source

• Completed

  Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase

  NCT01699217· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source

• Completed

  Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma

  NCT01208766· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Fabry disease3 works · 0 trials